Welcome to our dedicated page for Niagen Bioscience news (Ticker: NAGE), a resource for investors and traders seeking the latest updates and insights on Niagen Bioscience stock.
Niagen Bioscience, Inc. (NASDAQ: NAGE) is a bioscience company focused on NAD+ (nicotinamide adenine dinucleotide) science and healthy aging, and its news flow reflects that specialization. Company announcements frequently highlight developments around its patented nicotinamide riboside ingredient Niagen®, the Tru Niagen® consumer supplement line, and the Niagen Plus™ intravenous and injectable platform.
Readers following NAGE news can expect updates on product launches and line extensions, such as Tru Niagen Beauty, which combines Niagen with clinically studied ingredients to support the appearance of hair, skin, and nails. News items also cover commercial partnerships and distribution milestones, including the expansion of pharmaceutical-grade Niagen Plus IV and injections into hundreds of clinics and wellness centers across the United States.
Because Niagen Bioscience emphasizes evidence-based positioning, a significant portion of its news relates to clinical and scientific progress. This includes publication of randomized controlled trials using Niagen in specific populations, summaries of peer-reviewed research on NAD+ biology, and the evolution of educational platforms like AboutNAD®, which curates NAD+ research for consumers, clinicians, and scientists.
Investors and observers will also find regular coverage of financial and corporate developments, such as quarterly earnings releases, changes to full-year outlook, share repurchase authorizations, and intellectual property transactions involving core nicotinamide riboside patents. For anyone tracking the NAD+ category, the NAGE news page offers an ongoing view into how Niagen Bioscience advances its science, expands its product ecosystem, and manages its capital and IP strategy. Bookmark this page to monitor new studies, product initiatives, and regulatory or market updates that the company discloses over time.
Niagen Bioscience (NASDAQ:NAGE) announced a first-of-its-kind partnership with OneSpaWorld (NASDAQ:OSW) to offer pharmaceutical-grade Niagen IV at more than 80 Medi-Spa clinics aboard high-end cruise ships, expanding Niagen Plus reach to on-vacation consumers.
The Niagen IV aqueous formulation is stated to enable 75% shorter infusion times, a faster rise in NAD+ blood levels, a newly granted patent for IV/injectable methods of use, and 500 mg product availability via a U.S. FDA-registered outsourcing facility.
Niagen Bioscience (NASDAQ: NAGE) increased its share repurchase program authorization from $10 million to $20 million, with approximately $2.6 million repurchased through March 17, 2026. The program runs through October 31, 2027 unless earlier modified, suspended, or terminated.
Repurchases may be executed opportunistically via open market or negotiated transactions and do not obligate the company to buy any specific amount. Additional repurchase details will appear in the company’s periodic SEC reports.
Niagen Bioscience (NASDAQ: NAGE) will present at the 38th Annual ROTH Conference in Dana Point, California, March 22–24, 2026.
CEO Rob Fried will join the Technologies Advancing Healthy Aging panel on March 23 at 2:00 PM PT (5:00 PM ET), and management will hold one-on-one investor meetings. The panel will be livestreamed at www.event.summitcast.com.
Niagen Bioscience (NASDAQ: NAGE) announced its external research program surpassed 300 material transfer agreements, supporting research at >200 institutions across 34 countries and contributing to 45 published human clinical studies.
The program has produced >225 peer-reviewed publications, an estimated $200M+ in third-party research value, and a patent portfolio of 50+ granted patents, reinforcing Niagen's research footprint in NAD+ science.
Niagen Bioscience (NASDAQ: NAGE) launched the Niagen Skincare Innovation Lab and debuted Niagen NanoCloud, a limited-release, dermatologist-tested topical powered by patented Niagen (nicotinamide riboside).
The waterless, single-use sachet format preserves Niagen until activation; a 30-sachet box is priced at $59 and is available on Tru Niagen’s website. A 6-week consumer study (n=37) reported visible improvements starting in two weeks.
Niagen Bioscience (NASDAQ:NAGE) reported 2025 results: net sales +30% to $129.4M, Tru Niagen sales of $97.7M, gross margin up 250 bps to 64.3%, net income +103% to $17.4M, and adjusted EBITDA +139% to $20.4M. Cash totaled $64.8M at year-end with no borrowings. The company sold its analytical reference standards segment for approximately $6.0M in Feb 2026 and expects 2026 net sales growth of 10–15% (ex‑sold segment).
Operational moves included acquisition of NR patents from Queen’s University Belfast, a Truemed HSA/FSA partnership, a Tru Niagen Beauty launch, and positive long COVID clinical trial signals.
Niagen Bioscience (NASDAQ: NAGE) announced the sale of its ChromaDex Reference Standards business to LGC in an all-cash transaction completed on February 24, 2026. The divestiture is intended to streamline operations and allow the company to exit non-core activities to focus on NAD+ science, IP, and commercial growth in the longevity sector.
The company says proceeds will be reallocated toward patented Niagen® solutions, clinical and consumer channels, and core R&D and commercialization efforts.
Niagen Bioscience (NASDAQ: NAGE) announced U.S. Patent No. 12,558,367 covering methods of use for nicotinamide riboside (Niagen) in intravenous and injectable formulations, with expected protection through 2044. The patent covers aqueous IV formulations, administration parameters, select NR salt forms, and combination uses.
According to the company, the grant strengthens its IP moat for IV/injectable NAD+ precursors, supports commercial expansion and partnerships, and complements a portfolio of over 100 patents; Niagen IV is available at more than 1,200 U.S. clinics.
Niagen Bioscience (NASDAQ: NAGE) is the premiere sponsor of the inaugural NAD for Health: Opportunities & Challenges conference hosted by the University of Copenhagen, March 23–25, 2026. The three-day scientific forum will gather researchers, clinicians, and industry to advance NAD+ translation, trial design, and biomarkers.
Niagen Bioscience (NASDAQ: NAGE) will report fourth quarter and full year 2025 financial results after market close on Wednesday, March 4, 2026. Management will host an investor conference call the same day at 4:30 p.m. ET to review results and provide a business update.
The live webcast and dial-in will be available, with replay from 7:30 p.m. ET on March 4, 2026 through 11:59 p.m. ET on March 11, 2026. Call participants are asked to join at least 10 minutes early.